ArticleUnited European gastroenterology journal2026
Longitudinal Surveillance of Gastric Polyposis in Familial Adenomatous Polyposis: Incidence, Progression, and Endoscopic Outcomes.
Article in United European gastroenterology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric manifestations of familial adenomatous polyposis (FAP) have traditionally been considered of limited relevance in Western populations, with surveillance focused on duodenal disease. Recent data suggest that progressive gastric polyposis, particularly in the proximal stomach, may be associated with dysplasia and carcinoma. We aimed to characterize longitudinal gastric phenotype evolution and compartment-specific risk in a contemporary Western FAP cohort.
methodsWe conducted a retrospective longitudinal cohort study of patients with genetically confirmed FAP undergoing structured upper gastrointestinal surveillance between 2019 and 2023. Gastric phenotypes were assessed separately for the fundus/corpus and antrum. Fundic gland polyp (FGP) burden was recorded semiquantitatively. Gastric dysplasia and carcinoma were analyzed as compartment-specific outcomes.
resultsA total of 299 patients (1281 upper endoscopies; mean follow-up 2.6 years) were included. Fundic/corpus polyposis was present in 81.9% of patients at the baseline. During follow-up, the FGP burden increased substantially, with more than 100 polyps observed in 52.2% of patients during their 5th-year follow-up. Fundic/corpus dysplasia increased from 10.7% at baseline to 40.0% (annual point prevalence) by year 5 and was independently associated with a baseline FGP burden > 200 polyps. Gastric adenocarcinoma occurred in 6 patients (2.0%), predominantly in the proximal stomach and in the setting of extensive polyposis, with poor outcomes. In contrast, antral dysplasia followed a more indolent course. DISCUSSION: In FAP, gastric disease is dynamic and compartment-specific. Progressive fundic gland polyposis is associated with a high-risk phenotype for proximal gastric neoplasia, supporting phenotype-driven gastric surveillance strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.